Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
4.240
+0.240 (6.00%)
At close: Dec 5, 2025, 4:00 PM EST
4.220
-0.020 (-0.47%)
After-hours: Dec 5, 2025, 7:29 PM EST
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 3 or -15.00% compared to the previous year.
Employees
17
Change (1Y)
-3
Growth (1Y)
-15.00%
Revenue / Employee
n/a
Profits / Employee
-$3,304,385
Market Cap
310.93M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RLMD News
- 2 days ago - Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewsWire
- 22 days ago - Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates - GlobeNewsWire
- 4 weeks ago - Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 - GlobeNewsWire
- 4 weeks ago - Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer - GlobeNewsWire
- 2 months ago - Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 - GlobeNewsWire
- 2 months ago - Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire